Therapeutics & Vaccines

DEGRADATION TARGETING AGENTS AND USES THEREOF

View U.S. Patent Application Publication No. US-2026-0062453 in PDF format.

WARF: P250015US03

Inventors: Gaelen Hess, Grace Boyum

The Invention

UW-Madison researchers have discovered two peptides, HLTF;zf-C3HC4 and RO52;zf-C3HC4 (hereafter referred to as the HLTF peptide and the RO52 peptide) which, when tethered to a protein induce degradation of that protein. Both the HLTF and RO52 full length proteins are E3 ligases which ubiquitinate protein targets, and the zf-C3HC4 (aka RING finger) domains of those proteins are the peptides relevant to the present invention. So far, the inventors have tethered the HLTF peptide to two different degradation targets, Cas9 and BFP, and have tethered the RO52 peptide to BFP, and shown that the targets are degraded in several different cell lines (K562, HEK293T, and HeLa cells).

Tech Fields

- Research Tools : Protein interactions & function
- Therapeutics & Vaccines : Other therapeutic technologies

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847